Invasive Aspergillosis as an Under-recognized Superinfection in COVID-19

George R Thompson Iii; Oliver A Cornely; Peter G Pappas; Thomas F Patterson; Martin Hoenigl; Jeffrey D Jenks; Cornelius J Clancy; M Hong Nguyen

doi:10.1093/ofid/ofaa242

Invasive Aspergillosis as an Under-recognized Superinfection in COVID-19

Open Forum Infect Dis. 2020 Jun 19;7(7):ofaa242. doi: 10.1093/ofid/ofaa242. eCollection 2020 Jul.

Authors

George R Thompson Iii^{1

2}, Oliver A Cornely^{3

4

5

6}, Peter G Pappas⁷, Thomas F Patterson^{8

9}, Martin Hoenigl^{10

11}, Jeffrey D Jenks¹⁰, Cornelius J Clancy^{12

13}, M Hong Nguyen¹³

Affiliations

¹ Department of Internal Medicine, University of California Davis Medical Center, Davis, California, USA.
² Division of Infectious Diseases and Department of Medical Microbiology and Immunology, University of California Davis Medical Center, Davis, California, USA.
³ Department of Internal Medicine, University Hospital of Cologne, Cologne, Germany.
⁴ German Centre for Infection Research (DZIF) partner site Bonn-Cologne, Cologne, Germany.
⁵ CECAD Cluster of Excellence, University of Cologne, Cologne, Germany.
⁶ Clinical Trials Center Cologne, University Hospital of Cologne, Cologne, Germany.
⁷ Department of Internal Medicine, Division of Infectious Diseases, University of Alabama at Birmingham, Birmingham, Alabama, USA.
⁸ University of Texas Health Science Center at San Antonio, San Antonio, Texas, USA.
⁹ South Texas Veterans Health Care System, San Antonio, Texas, USA.
¹⁰ Division of Infectious Diseases and Global Health, University of California San Diego, La Jolla, California, USA.
¹¹ Section of Infectious Diseases and Tropical Medicine, Medical University of Graz, Graz, Austria.
¹² VA Pittsburgh Healthcare System, Pittsburgh, Pennsylvania, USA.
¹³ Department of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.

Abstract

Pulmonary aspergillosis has been increasingly reported following severe respiratory viral infections. Millions have been infected by SARS-CoV-2, placing large numbers of patients at-risk for COVID-19 associated pulmonary aspergillosis (CAPA). Prompt recognition of this syndrome and is paramount to improve outcomes.